Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 73 Shiller PE Ratio is 10.91 as of Sep. 01, 2026, which is 30% below its 10-year median of 15.58. GuruFocus rates XSWX:BIIB with a GF Score™ of 73/100 and a GF Value™ of CHF156.65. The stock has 10 warning signs investors should review. Among 526 Drug Manufacturers companies, Biogen ranks better than 85.17% on this metric.
As of today (2026-09-01), Biogen's current share price is CHF173.46. Biogen's E10 for the quarter that ended in Jun. 2026 was CHF15.90. Biogen's Shiller PE Ratio for today is 10.91.
The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:
XSWX:BIIB'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 5.56 Med: 15.58 Max: 41.15
Current: 10.99
During the past years, Biogen's highest Shiller PE Ratio was 41.15. The lowest was 5.56. And the median was 15.58.
XSWX:BIIB's Shiller PE Ratio is ranked better than 85.17% of 526
companies
in the Drug Manufacturers industry
Industry Median: 25.59
vs XSWX:BIIB: 10.99
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Biogen's adjusted earnings per share data for the three months ended in Jun. 2026 was CHF0.528. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF15.90 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Biogen Shiller PE Ratio Related Terms
Biogen Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Biogen's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BIIB vs OGN, AMRN, NSRX: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Biogen's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Biogen's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Biogen's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Biogen (XSWX:BIIB) has a Shiller PE Ratio of 10.91 as of Sep. 01, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Biogen and its competitors. This is 30% below median its historical median of 15.58. Over the past decade, Biogen's Shiller PE Ratio has ranged from 5.56 to 41.15. According to the industry distribution chart, Biogen ranks #78 out of 526 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Biogen's Shiller PE Ratio too high?
Biogen's current Shiller PE Ratio of 10.91 is 30% below median its 10-year median of 15.58. Over the past 10 years, this metric has ranged from a low of 5.56 to a high of 41.15. The Drug Manufacturers industry median Shiller PE Ratio is 25.59. Biogen's value of 10.91 is 57.4% below this industry median. Based on the distribution chart, Biogen ranks #78 out of 526 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogen has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Shiller PE Ratio compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #78 out of 526 companies for Shiller PE Ratio. This places Biogen in the top 15% of its industry — outperforming the majority of peers. The industry median Shiller PE Ratio is 25.59. Biogen's value of 10.91 is 57.4% below this benchmark. Historically, Biogen's own Shiller PE Ratio has ranged from 5.56 to 41.15 over the past decade. While the company's 10-year median is 15.58 vs. the industry median of 25.59, Biogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.59, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current Shiller PE Ratio of 10.91 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current Shiller PE Ratio is 10.91, which is 30% below median its own 10-year median of 15.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Shiller PE Ratio of 10.91. The stock's GF Value™ is CHF156.65, compared to a current price of CHF173.46 — trading 10.7% above its estimated fair value. The current Shiller PE Ratio is 10.91, which is 30% below median its 10-year median of 15.58 and 57.4% below the Drug Manufacturers industry median of 25.59. Biogen's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Shiller PE Ratio is 10.91 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 10.7% above its estimated GF Value™ of CHF156.65.
Key valuation signals for XSWX:BIIB:
Shiller PE Ratio: 10.91 (30% below median its 10-year median of 15.58)
GF Value™: CHF156.65 vs. price of CHF173.46 (10.7% above fair value)
Industry Position: 57.4% below the Drug Manufacturers median (#78 of 526)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score
Get the complete analysis for XSWX:BIIB
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
